ICIs work principally by overcoming immune tolerance against the tumor, mediated by inhibitory molecules such as PD-1, PD-L1, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and enhancing the body's own immune response [10]. The gene discussed is CTLA4; the disease is neoplasm.